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n Abstract: Bias in referral patterns and variations in multi-disciplinary management may impact breast conservation
therapy (BCT) rates between hospitals. Retrospective studies of BCT rates are limited by their inability to differentiate indi-
cated mastectomies versus those chosen by the patient. Our prospective breast cancer data base was queried for patients
with invasive breast cancer who underwent surgical therapy at the University of Michigan over a 3-year period. Demograph-
ics, stage and histology were recorded along with the reason mastectomy was performed, categorized as ‘‘by need’’ (con-
traindication to BCT) or ‘‘by choice.’’ Multivariate analysis was used to identify factors significantly associated with
mastectomy by choice. BCT was associated with tumor size, histology and nodal status, but not older age, either by choice
or by need. Of the 34% of patients initially felt to be poor candidates for BCT, it was absolutely contraindicated in 44%,
while 56% were thought to have a tumor-to-breast size ratio too large for successful BCT. Of this latter group, 80% under-
went neo-adjuvant chemotherapy in an attempt to downstage the primary tumor and perform BCT, which was successful in
over half the patients. For the patients initially thought to be good candidates for BCT, only 15% chose to undergo mastec-
tomy, while 5% eventually required mastectomy due to failed attempts to achieve negative margins. Overall, the BCT rate
was 63%, however without the use of neo-adjuvant chemotherapy, the BCT rate would have been only 53%. At a tertiary
referral center, BCT rates are driven more by contraindications than patient choice, and may be heavily skewed towards
mastectomy due to referral patterns. In addition to tumor factors such as stage and histology, BCT rate can be dramatically
impacted by neo-adjuvant chemotherapy or genetic counseling. Examining BCT rates alone as a measure of quality, there-
fore, is not an appropriate standard across institutions serving diverse populations. n
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The evolution of breast cancer surgery from radicalmastectomy to modified radical mastectomy and
now breast conservation therapy (BCT) has been
accompanied by randomized controlled trials demon-
strating the oncologic safety and therapeutic efficacy
of less radical procedures. In 1990, a National Insti-
tutes of Health consensus statement recommended
BCT with radiation for the majority of women with
stages I and II breast cancers (1). Increased screening
and earlier diagnosis have increased the number of
women presenting with early stage breast cancer, and
with the introduction and increased use of neo-adju-
vant chemotherapy to downstage primary breast
cancers, even more women may ultimately avoid
mastectomy.
Despite these facts, many patients with breast can-
cer are still being treated by mastectomy. Many stud-
ies have examined patient and physician factors that
might influence use of BCT versus mastectomy (2–6).
There has also been discussion of using BCT rates as a
measure of quality for comparing breast cancer care
between hospitals (7). However, many mastectomies
are performed because of absolute contraindictions to
BCT.
At the University of Michigan, our multi-disciplin-
ary approach is heavily weighed towards promoting
breast conservation, the success of which has been
well documented (8–10). Despite this philosophical
approach, the nature of our practice, in large part
comprised of second opinions, may impact our breast
conservation rate. Breast cancer patients initially
offered lumpectomy might be more likely to stay with
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their primary surgeon, while women told they require
mastectomy might be more likely to seek a second
opinion at a referral center (and remain at that center
for surgery). This could influence the breast conserva-
tion rate, which is particularly concerning if insurance
companies seek to use this statistic as a yardstick of
quality. With this information in mind, we sought to
determine the proportion of patients undergoing BCT
and the salient reasons for the surgical treatment deci-
sions made by patients and their surgeons. In doing
so, we demonstrate the importance of differentiating
patients who require mastectomy from patients who
are eligible for BCT but choose mastectomy, particu-
larly when evaluating factors that are associated with
BCT rates.
MATERIALS AND METHODS
All biopsy-proven breast cancer patients seen at the
University of Michigan Comprehensive Cancer Center
are presented at a multi-disciplinary tumor board
composed of surgical, medical, and radiation oncolo-
gists, radiologists, pathologists, and associated support
staff. Patients who choose to obtain their surgery at
the University of Michigan are then entered into an
institutional data base. Our prospective breast cancer
data base was queried for all patients with breast can-
cer who underwent surgical therapy at the University
of Michigan over a 3-year period, between January 1,
2003 and December 31, 2005. Male breast cancer
patients and patients with lobular carcinoma in situ
were excluded. In addition, all women with synchro-
nous, bilateral breast cancers were excluded, as this
might affect a woman’s choice of surgical therapy.
This study was approved by the Institutional Review
Board at the University of Michigan.
Data were collected on patient demongraphics, stage
(as delineated by the sixth AJCC Staging Manual) and
histologic diagnosis. Reasons for mastectomy were
recorded and categorized as (i) BCT attempted but
negative margins could not be achieved, (ii) radiation
therapy contraindicated (pregnancy, collagen-vascular
disease, previous radiation), (iii) presence of diffuse
microcalcifications on mammography, (iv) evidence of
multicentric tumors (defined as tumors in two quadrants
of the breast or multiple tumors that could not be
encompassed in one lumpectomy), (v) poor tumor-to-
breast size ratio, (vi) other ⁄ unknown, and (vii) BCT
eligible but patient preference for mastectomy. Some
of these reasons were further grouped to produce the
category, ‘‘Mastectomy by need.’’ This category inclu-
ded women for whom breast conserving therapy was
contraindicated because of multicentricity, widespread
calcifications, inability to undergo radiation therapy, or
failed attempts at BCT. Neither strong family history
nor documented genetic predisposition were considered
absolute contraindications to BCT. Tumor size was not
considered an absolute contraindication for patients
with invasive carcinoma, as neo-adjuvant chemotherapy
was an option, but was considered a ‘‘mastectomy by
need’’ for ductal carcinoma in situ (DCIS).
RESULTS
Between January 2003 and December 2005, 993
patients had surgery at the University of Michigan
Medical Center for unilateral invasive breast cancer or
DCIS. There were 161 evaluable cases of in situ dis-
ease and 784 evaluable cases of invasive disease.
Forty-eight cases were excluded for incomplete data.
Over half of the invasive cases were T1 tumors. The
average age was 54.2 ± 12.7 years of age, ranging
from 17 (a case of secretory carcinoma) to 95. The
majority of women were white (86%). Patient charac-
teristics are summarized in Table 1.
For the entire study population, the breast conser-
vation rate was 63%. The breast conservation rate
was similar between patients with DCIS (68%) and
patients with invasive cancer (62%). These percent-
ages include both patients who required mastectomy
(contraindications to BCT) and those who chose mas-
tectomy. Among breast conservation eligible patients
(those who had no contraindications to BCT), the
Table 1. Study Population
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BCT rate was 83% for DCIS and 78% for invasive
cancer.
To get a better idea of what drove the breast con-
servation rate, we compared the reasons for mastec-
tomy across patients with invasive cancer and those
with DCIS (Table 2). In both groups of patients, the
primary reason for mastectomy was patient choice.
For patients with DCIS, the next most common reason
for mastectomy was diffuse calcifications on mam-
mography, representing more than one-quarter of
mastectomies (27%). For patients with invasive can-
cer, over 70% were deemed poor candidates for breast
conservation. The most common reason for this was
tumor size (22%). This category excludes patients
who were downstaged by neo-adjuvant chemotherapy
and underwent breast conservation, but does include
patients who either chose not to undergo neo-adjuvant
chemotherapy, or underwent mastectomy after neo-
adjuvant chemotherapy. The ultimate fate of the
patients with invasive disease is outlined in Figure 1.
Two-thirds of patients with invasive disease were
felt to be good candidates for breast conservation on
initial evaluation. Of these patients, over 80% went
on to successful breast conservation while 15% chose
to undergo mastectomy. The remaining 5% of
patients opted for BCT but failed attempts to achieve
negative margins ultimately led to mastectomy. Of the
initial one third of patients with invasive cancer who
were felt to be poor candidates for BCT, nearly one-
half had an absolute contraindication (44%) while
just over one-half (56%) were thought to have a
tumor-to-breast size ratio too large for successful
breast conservation. For these patients with large
tumors, 20% opted to proceed directly with mastec-
tomy while 80% underwent neo-adjuvant chemother-
apy. Most undertook chemotherapy in an attempt to
downstage the primary tumor for breast conservation,
although 14 patients underwent neo-adjuvant chemo-
therapy knowing mastectomy would be indicated after
chemotherapy. Of the patients who had neo-adjuvant
chemotherapy, BCT was successfully performed in
52%. Looking at the entire population of patients
with invasive cancer, without the use of neo-adjuvant
chemotherapy the breast conservation rate would have
been only 53%.
To better clarify those factors that impacted
whether a woman with invasive breast cancer under-
went breast conservation or mastectomy, we analyzed
Table 2. Reasons for Mastectomy for Patients with Invasive Carcinoma and DCIS
Population Patient choice Tumor size Multicentric Diffuse calcifications Attempt at BCT failed Could not have XRT Other or unknown
Overall (379) 31% 19% 15% 17% 9% 5% 4%
Invasive (319) 28% 22% 16% 15% 9% 6% 5%
DCIS (60) 45% 6% 12% 27% 4% 4% 2%
BCT, breast conservation therapy; XRT, radiation therapy; DCIS, ductal carcinoma in situ.
Figure 1. Pathways from diagnosis to final
surgery for patients with invasive breast
cancer.
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both BCT versus mastectomy (regardless of reason)
and BCT versus mastectomy by need. Significant pre-
dictors of BCT included older patient age, ductal his-
tology, decreasing T-stage and the absence of lymph
node involvement. Table 3 shows the odds ratios for
these features in the BCT, mastectomy by choice and
maststectomy by need groups. Across the population
as a whole, regardless of the reason women underwent
mastectomy, these features were significant on both
univariate and multivariate logistic regression models.
However, when we compared BCT to mastectomy
only among women who had a choice, eliminating
those patients who were not candidates for BCT, age
was no longer a significant covariate on multivariate
analysis (Table 4). This was true whether age was
modeled as a continuous covariate or in categorical
decades. For women over the age of 40, the breast
conservation rate in each decade group is nearly
identical. Older age was not associated with either an
increased need for mastectomy, or an increased desire
for mastectomy (Fig. 2).
Table 5 shows the use of contralateral prophylactic
mastectomy among women undergoing mastectomy
by choice and by need. Over half (56%) of patients
under the age of 40 who chose a mastectomy actually
chose to undergo bilateral mastectomies. This number
decreased with increasing decades of life and was sub-
stantially lower among women who were not candi-
dates for breast conservation.
DISCUSSION
Although many surgeons were initially skeptical of
breast conservation, once multiple randomized trials
established its safety, the use of breast conservation
slowly began to climb. This rise was further fueled by
widespread mammographic screening and the associ-
ated decreases in the median tumor size at diagnosis.
Today, the majority of women diagnosed with breast
cancer are eligible for breast conservation, and for
stage I or II breast cancer, breast conservation is con-
sidered by many to be the standard of care. With this
in mind, a surgeon’s, practice’s or hospital’s breast
conservation rate – the percentage of newly diagnosed
breast cancer patients treated by lumpectomy and
whole-breast irradiation, has become a marker of
appropriate care. The breast conservation rate has
been used to compare cancer care among various
regions in the country, patients of various races or
socioeconomic status, community hospitals versus
academic centers, fellowship-trained versus general
surgeons, etc (11–18). Today, insurance companies
are interested in using breast conservation rates as a
method of assessing quality of breast cancer care
(7,19). Much of this is based on the idea that mastec-
tomy is a less desirable operation, and its use is
Table 3. Analytic Sample Characteristics for










Prophylactic contralateral mastectomy: n (%)
Yes 0 45 (31.9) 22 (13.8)
No 483 (100) 96 (68.1) 138 (86.3)
Race: n (%)
White 421 (62.0) 117 (17.2) 141 (20.8)
Black 32 (65.3) 7 (14.3) 10 (20.4)
Asian ⁄ Pacific Islander 10 (40.0) 10 (40.0) 5 (20.0)
Other 20 (64.5) 7 (22.6) 4 (12.9)
Age
Mean 55.4 53.5 51.1
Median 55 53.5 50
Minimum–Maximum 24–89 25–95 17–89
Age decade: n (%)
£40 46 (41.4) 25 (22.5) 40 (36.0)
41–50 130 (61.6) 36 (17.1) 45 (21.3)
51–60 154 (66.4) 39 (16.8) 39 (16.8)
61–70 96 (69.1) 23 (16.6) 20 (14.4)
71+ 57 (62.6) 18 (19.8) 16 (17.6)
Histology: n (%)
Ductal 398 (63.9) 101 (16.2) 124 (19.9)
Ductal with lobular
features
27 (61.4) 8 (18.2) 9 (20.5)
Lobular 32 (42.1) 26 (34.2) 18 (23.7)
Other 26 (63.4) 6 (14.6) 9 (22.0)
Tumor size (T-stage)
1 344 (71.7) 63 (13.1) 73 (15.2)
2 125 (56.8) 44 (20.0) 51 (23.2)
3 12 (22.2) 24 (44.4) 18 (33.3)
4 2 (6.7) 10 (33.3) 18 (60.0)
Positive lymph nodes
Yes 129 (45.0) 78 (27.2) 80 (27.9)
No 342 (71.3) 61 (12.7) 77 (16.0)
Unknown 12 (70.6) 2 (11.8) 3 (17.7)
BCT, breast conservation therapy.
Table 4. Univariate and Multivariate Association
of Covariates with Surgical Procedures for Inva-
sive Breast Cancer
Covariate











<0.0001 0.0014 0.1012 0.1117
T-stage <0.0001 <0.0001 <0.0001 <0.0001
Histology 0.0046 0.0290 0.0008 0.0028
Nodal involvement <0.0001 0.0002 <0.0001 0.0002
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somehow a failure on the part of the surgeon, either
by not offering it appropriately or by not informing
patients well enough that they can choose the ‘‘right’’
operation. This has prompted a wealth of literature
on what drives patient decision making when choos-
ing between BCT and mastectomy and methods to
decrease the ‘‘over-use’’ of mastectomy (2–4,20).
A significant problem arises when comparing breast
conservation rates, and evaluating factors associated
with BCT, using data from large data bases. Because
the end point is usually whether a patient had BCT,
without consideration of the reasons a woman under-
went one treatment or the other, this might not accu-
rately represent the institution’s approach to breast
cancer surgery. Some women who are eligible for
breast conservation choose to undergo mastectomy,
and while some of the reasons for these choices may
be based on incorrect assumptions (such as the likeli-
hood of recurrence or an overestimation of the risks
of radiation therapy), sometimes the choice to
undergo mastectomy is a well-thought out and
legitimate decision (such as a desire to avoid the
inconvenience and side effects of radiation). More
importantly, many women with breast cancer are not
eligible for breast conservation based on a number of
absolute contraindications. These include an inability
to undergo radiation, multicentric disease, or wide-
spread microcalcifications on mammography. A third
group of women might desire breast conservation, but
ultimately fail multiple attempts to obtain negative
margins around both the invasive and in situ compo-
nents of their disease.
Overall, the breast conservation rate over the
3-year period studied was 63%; 68% for DCIS and
62% for invasive cancer. This is consistent with that
described in the literature, although this number alone
does not seem to imply a particularly aggressive use
of breast conservation. To analyze this further, we
divided mastectomy patients into two catego-
ries—those who had a ‘‘mastectomy by need,’’ includ-
ing patients with an absolute contraindication to
mastectomy or who failed BCT, and those who had a
‘‘mastectomy by choice,’’ those BCT eligible patients
who ultimately chose mastectomy. More than half of
the mastectomies performed were by need, driven by
contraindications to BCT, and representing approxi-
mately 1 ⁄ 5 of our patient population. How this com-
pares to other cancer centers or community hospitals
is not clear, but it is evident that referral patterns will
impact breast conservation rates.
Other aspects of our practice also impacted breast
conservation rates. Driving a higher breast conserva-
tion rate was our use of neo-adjuvant chemotherapy.
Approximately 20% of our patients were thought to
have a tumor size to breast size ratio that, while not
Figure 2. Breast conservation versus mastectomy by age.
Table 5. Use of Prophylactic Mastectomy among
Women Undergoing Mastectomy
Mastectomy by choice (%) Mastectomy by need (%)
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an absolute contraindication to BCT (and not catego-
rized as a ‘‘mastectomy by need’’), would give a poor
cosmetic outcome. Most of these patients were given
neo-adjuvant chemotherapy, and nearly half of those
patients ultimately underwent breast conservation.
Without neo-adjuvant chemotherapy, the breast con-
servation rate would have been only 53%, well below
the national average. Thus institutions with a less
aggressive use of neo-adjuvant chemotherapy, or
patient populations less willing to undergo neo-adju-
vant chemotherapy, might have lower breast conserva-
tion rates.
In contrast, the breast conservation rate among
younger patients was strongly driven by a desire for
prophylaxis and BCT eligible patients undergoing
bilateral mastectomies. This may, in part, be due to
an aggressive use of genetic counseling during the
initial evaluation of the breast cancer patient. Again,
institutions with older populations or those not offer-
ing genetic counseling to patients may ultimately have
higher breast conservation rates.
The importance of separating ‘‘mastectomy by need’’
and ‘‘mastectomy by choice’’ when analyzing breast
conservation rates becomes apparent when multivariate
analysis of those factors predictive of BCT is performed.
When one looks at the entire population, including all
mastectomy patients, four factors are significantly asso-
ciated with BCT on multivariate logistic regression
analysis; tumor size, patient age, histology (ductal
versus lobular) and lymph node involvement. However,
when one performs the same analysis, restricted to
patients who had a choice in treatment, age is no longer
a significant covariate. It becomes apparent that analy-
ses such as these, performed on large national or insur-
ance company datasets not separating mastectomy by
need from mastectomy by choice, might give misleading
or incorrect results.
Several other misconceptions regarding breast con-
servation rates also became apparent in this review,
specifically the impact of age and histology. Several
studies have addressed the impact of age on breast
cancer treatment, including not only the use of breast
conserving surgery but also the use of adjuvant
chemotherapy and radiation therapy (21–23). Many
physicians are under the impression that older patients
are less concerned with appearance or the psycho-
social impact of mastectomy than their younger coun-
terparts, a misconception reinforced by earlier studies
suggesting a lower use of BCT in older populations
than in younger patients (21–23). However, our find-
ings were quite the opposite. Figure 2 illustrates that
older women neither require mastectomy, nor choose
mastectomy, at a higher rate than their younger coun-
terparts. In fact, it was younger women that more
often chose mastectomy over BCT, driven in large
part by the desire for bilateral mastectomies for pro-
phylaxis. This would suggest that, if all information is
presented appropriately, patient populations with an
older median age should have higher breast conserva-
tion rates, not lower rates as many might assume, a
phenomenon that has been recently observed in other
settings as well (17).
Nodal involvement was associated with an
increased use of mastectomy, although the presence of
nodal disease is not a contraindication to BCT. This
group of patients included those with clinical evidence
of nodal involvement and those with positive sentinel
lymph nodes (approximately 8% of patients opted not
to have axillary staging). One possible explanation is
the strong association between tumor size (which
clearly does impact BCT rates) and nodal metastases.
However, one would expect nodal involvement to lose
significance on multivariate analysis. Another possible
explanation is that women who have ‘more aggressive
disease’ may be pushed towards what they conceive to
be more aggressive surgery (mastectomy versus lump-
ectomy). As there is no evidence that a mastectomy
provides a survival advantage over BCT in node posi-
tive patients, this may represent a failure in communi-
cation between the surgeon and the patient.
Lobular histology was associated with an increased
use of mastectomy. While this may not be surprising,
the reasons for this, as shown in Table 6, might not
be what many surgeons expect. Because the size of
lobular carcinomas are often larger than what is seen
on conventional imaging, many surgeons assume that
Table 6. Reasons for Mastectomy for Ductal Carcinoma versus Lobular Carcinoma
Population Patient choice Tumor size Multicentric Diffuse calcifications Attempt at BCT failed Could not have XRT Other or unknown
Ductal (225) 30% 20% 14% 18% 8% 6% 5%
Lobular (44) 34% 25% 25% 2% 7% 5% 2%
BCT, breast conservation therapy; XRT, radiation therapy.
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patients with lobular carcinoma undergo more mastec-
tomies because of failed attempts at breast conserva-
tion. However, the BCT failure rate was identical for
ductal and lobular histologies (8% and 7% respec-
tively). Initial tumor size was a more common reason
for mastectomy in patients with invasive lobular carci-
noma, slightly due to the fact that lobular carcinomas
were downstaged by neo-adjuvant chemotherapy less
frequently than ductal carcinomas. In addition, more
women with invasive lobular carcinoma had multicen-
tric disease, precluding breast conservation.
In conclusion, although BCT is advocated as a
superior therapeutic course for eligible patients, exam-
ining BCT rates as a measure of quality of care across
institutions can be misleading unless other factors
are considered. As we move towards a performance-
oriented compensation model, the consequences of
selecting fair and accurate assessment tools is incalcu-
lable. Breast conservation surgery is clearly dependent
on appropriate patient selection; the patient popula-
tions at comprehensive cancer centers may be heavily
skewed towards mastectomy due to the complexities
of their disease. The use of BCT as a quality assess-
ment tool may also increase the use of BCT for
patients who are not good candidates, ultimately
detracting from their quality of life and overall sur-
vival. Prospectively categorizing the clinical reasons
women undergo mastectomy, and stratifying women
who need mastectomy from women who choose mas-
tectomy, should give a more accurate reflection of
practice patterns. Breast conservation rates are suit-
able for the assessment of an institution’s multi-disci-
plinary approach to breast cancer, especially when
factoring in the use of neo-adjuvant therapy or genetic
counseling, however BCT rates are a poor measure of
a center’s overall quality of cancer care.
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